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Abstract
Background: Tuberculosis (TB) incidence data in vaccine target populations, particularly adolescents, are important
for designing and powering vaccine clinical trials. Little is known about the incidence of tuberculosis among
adolescents in India. The objective of current study is to estimate the incidence of pulmonary tuberculosis (PTB)
disease among adolescents attending school in South India using two different surveillance methods (active and
passive) and to compare the incidence between the two groups.
Methods: The study was a prospective cohort study with a 2-year follow-up period. The study was conducted in
Palamaner, Chittoor District of Andhra Pradesh, South India from February 2007 to July 2010. A random sampling
procedure was used to select a subset of schools to enable approximately 8000 subjects to be available for
randomization in the study. A stratified randomization procedure was used to assign the selected schools to either
active or passive surveillance. Participants who met the criteria for being exposed to TB were referred to the
diagnostic ward for pulmonary tuberculosis confirmation. A total number of 3441 males and 3202 females between
the ages 11 and less than 18 years were enrolled into the study.
Results: Of the 3102 participants in the active surveillance group, four subjects were diagnosed with definite
tuberculosis, four subjects with probable tuberculosis, and 71 subjects had non-tuberculous Mycobacteria (NTM)
isolated from their sputum. Of the 3541 participants in the passive surveillance group, four subjects were diagnosed
with definite tuberculosis, two subjects with probable tuberculosis, and 48 subjects had non-tuberculosis
Mycobacteria isolated from their sputum. The incidence of definite + probable TB was 147.60 / 100,000 person years
in the active surveillance group and 87 / 100,000 person years in the passive surveillance group.
Conclusion: The incidence of pulmonary tuberculosis among adolescents in our study is lower than similar studies
conducted in South Africa and Eastern Uganda – countries with a higher incidence of tuberculosis and human
immunodeficiency virus (HIV) than India. The study data will inform sample design for vaccine efficacy trials among
adolescents in India.
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Background
The incidence of tuberculosis (TB) has declined globally
from 139 per 100,000 person years in 2005 to 126 per
100,000 person years in 2013. During the same period,
the overall incidence in India declined from 209 to 171
per 100,000 person years [1]. Even so, TB accounts for
approximately one million deaths every year globally, ac-
cording to a recent WHO report, of which 0.24 million
deaths were in India. India alone accounts for approxi-
mately 24 % of all incident TB cases globally [1]. One of
the most effective strategies for the control of tubercu-
losis is mass vaccination with an effective TB vaccine
[2–4]. The Bacillus Calmette-Guérin (BCG) vaccine has
been recommended at birth in high burden countries
based on its efficacy in reducing TB disease in children,
although efficacy wanes with time [5, 6]. Given that ex-
posure to tuberculosis increases with age in high burden
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countries and that there is an increase in the incidence
of TB disease in early adulthood, there is a need for the
development of a pre-exposure and/or a post-exposure
TB vaccine that could be administered to adolescents
prior to adulthood.
TB incidence data in vaccine target populations are
important for the design of late-phase vaccine clinical
trials. Little is known about the incidence of TB in ado-
lescents in India, although it has been reported that the
risk of acquiring TB disease after TB infection is higher
in adolescents compared to adults [7]. Based on the age-
stratified data available, the new smear positive case no-
tification in 2011 of individuals between 15 and 24 years
in India was approximately 0.13 million, which was
20.56 % of total smear positive cases among all age
groups in India [8].
The reported incidence of TB disease may be affected
by how it was detected. It is possible that in active sur-
veillance (periodic home visits), the disease is picked up
at an earlier stage by sputum culture (sputum collected
through either gastric lavage or induced sputum) even
though the participant might not have symptoms sug-
gestive of tuberculosis. In passive surveillance (where
participants self-report for a diagnostic evaluation), it is
more likely for TB to be diagnosed at a later stage when
symptoms suggestive of tuberculosis are present. While
there are obvious advantages to active surveillance, costs
and manpower are considerably higher. Therefore, the
present methodology was used to determine whether
less expensive passive surveillance would yield similar
estimates of TB incidence compared to active surveil-
lance. The results would have implications in the study
design of large field studies that test new TB vaccine
efficacy.
Objective of the present study
The study was designed to estimate the incidence of pul-
monary tuberculosis (PTB) disease among adolescents
attending school in South India by using two different
surveillance methods (active and passive).
Methods
Study setting
The study was conducted in the former Palamaner taluk
of Chittoor District of Andhra Pradesh in South India
approximately 135 km from Bangalore city from Febru-
ary 2007 to July 2010. The study area for this study con-
sisted of 397 population units, of which 384 were rural.
The estimated population at the time of the study was
250,000 [9]. The study area was chosen since the inci-
dence of tuberculosis in this area is fairly similar to na-
tional rates in India, and the out-migration rate is low
allowing for comprehensive follow-up.
Study design
The study was a prospective observational cohort study
with a 2-year follow-up period.
Sampling
From an initial list of schools registered with the Gov-
ernment (Mandal) Education Office in the region, a ran-
dom sampling procedure was used to select a subset of
schools to enable approximately 8000 subjects to be
available for randomization in the study. A stratified
randomization procedure was used to assign the selected
schools to either active or passive surveillance.
Randomization for the public high schools was stratified
by size of school, while the remaining schools were
stratified by type of school (private high school, private
junior college, or public junior college). The schools not
selected during the initial random sampling procedure
were also randomized using a similar stratified
randomization procedure to either active or passive sur-
veillance and were used only if the targeted number of
subjects were not enrolled from the selected subset of
schools.
Study participants
All adolescents aged ≥11 to <18 years attending 58 high
schools and four junior colleges (grades 7 through 12) in
the study area were approached. The total number of eli-
gible adolescents was 12,388. A decision to work in the
schools was made to ensure the consistent conduct of
this study and to minimize loss to follow-up.
Participants who indicated that they or their families
were likely to move from the study area during the pro-
posed 2 years of follow-up or who indicated that they
were unable to attend the follow-up session for the tu-
berculin skin test (TST) reading at baseline were ex-
cluded from the study.
Study procedures
Baseline assessment
At baseline, all participants underwent the following
procedures.
Questionnaires The parents or guardians were asked
about the participant’s clinical history, including BCG
immunization status, history of current or past TB, his-
tory of close contact of more than 8 h a week with an
adult with proven TB, current signs or symptoms of TB,
and history of hospitalizations during the last 6 months
and/or diagnosis of acute or chronic diseases. The ado-
lescents were asked to review the medical history pro-
vided by their parents or guardians and to provide
additional information, if any. Socio-demographic details
and indicators were also recorded during the interview,
including the parent’s / guardian’s occupation, education,
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and income; the subject’s gender, religion, date of birth,
and whether they were a member of a socially deprived
community; and the type of walls found in the subject’s
home, type of cooking fuel used, and the presence or ab-
sence of a household electricity connection.
Clinical assessments The presence or absence of a
BCG scar was noted. Height was measured to the closest
0.10 cm using a standard measuring tape with the sub-
ject standing against a wall in the Frankfurt plane;
weight was recorded in school clothes but without foot-
wear to the nearest 0.10 kg using a calibrated digital
weighing scale (Bhaseen Health Product Pvt. Ltd., Jalan-
dhar, India). Weight and height were used to compute
Body Mass Index (BMI) and to derive the BMI-for-age
z-scores as a measure of nutritional status. BMI for age
Z-score was calculated using the Anthroplus software
(Version 3.1, WHO, 2010). Based on the BMI for age
Z-score, participants were classified as Underweight
(BMI – Age Z-score less than or equal to −2), Over-
weight (BMI – Age Z-score greater than or equal to 1), or
Normal (BMI – Age Z-score between −2 to 1; does not in-
clude −2 or 1) [10].
Tuberculin skin test Designated trained research
nurses administered 0.10 ml of tuberculin containing
two TU Purified Protein Derivative (PPD) of RT 23 with
Tween 80 as a stabilizer (SPAN Diagnostic Ltd, Surat,
India) on the anterior surface of the forearm about two
to four inches below the elbow. A designated trained tu-
berculin reader made the reading visit between 48 and
96 h after the skin test was administered. A wider win-
dow of 4 days for tuberculin skin test evaluation was
used when the participant was unavailable for TST read-
ing within 72 h. Approximately 88 % of participants
were evaluated for the TST within 48 to 72 h; the
remaining participants were examined in the 4 day win-
dow. The skin test site was inspected in good light and
the maximum transverse diameter of the induration was
measured in millimetres using a transparent ruler cali-
brated in millimetres. The measurements were recorded
and documented along with the date and time.
Blood sample All participants provided a 29 ml blood
sample, which was processed and stored for immuno-
logical analyses. Hemoglobin was estimated at the time
of blood sampling using the Hemocue AB (HemoCue
India, New Delhi, India).
Surveillance of participants A stratified randomisation
procedure assigned the schools to either active or pas-
sive surveillance. Schools were chosen as the unit for
randomisation, rather than individuals, to avoid contam-
ination of follow-up type.
The participants in the active surveillance group were
followed-up every 3 months and asked for any signs or
symptoms of pulmonary TB and for any recent exposure
to a known case of TB. A blood draw was also per-
formed every 6 months. At the 1 year study visit, partici-
pants in the active surveillance group had a repeat TST.
The participants in the passive surveillance group were
educated about symptoms related to pulmonary TB and
asked to present to the diagnostic ward (DGW) if they
developed symptoms and/or were exposed to a known
case of tuberculosis.
In addition, all primary health care centres and hospi-
tals in the study area, as well as major referral hospitals
outside the study area, were visited once a week to de-
termine whether any of the study participants had been
diagnosed with PTB in the facility. To facilitate this
process, all participants were given a study ID card,
which indicated their enrolment into the study and in-
cluded the study physician’s contact details. The treating
physicians at the health centres were requested to con-
tact the study physician if they suspected PTB in the
participant.
At the final study visit (Day 720), the baseline proce-
dures were repeated among all participants in both the
active and passive surveillance groups.
Confirmation of TB
TB confirmation The participant is diagnosed with pul-
monary tuberculosis disease if the individual had (1) at
least one positive culture result [Isolation of Mycobacter-
ium tuberculosis (Mtb) from either one or both sputum
samples using the GenoType MTBC test kit (HAIN kit)]
or (2) one sputum smear result positive for acid fast ba-
cilli (AFB) and positive polymerase chain reaction (PCR)
for Mycobacterium tuberculosis or (3) two sputum smear
results positive for AFB, or (4) radiological evidence of
PTB on a chest x-ray [Posterior-anterior (PA) view] with
concurrent diagnosis by at least two radiologists.
If the participants had a recent history of positive TB
contact, had symptoms suggestive of pulmonary TB (un-
explained cough, unexplained fever, unexplained weight
loss, unexplained night sweats for more than 2 weeks,
and Haemoptysis), was diagnosed with pulmonary TB by
any other physician, or had a positive TST (TST
≥10 mm) during the baseline procedure or any of the
follow-up visits, they were referred to the base hospital
for further evaluation of PTB. On arrival to the base
hospital, the participant’s clinical history was reviewed
and a clinical evaluation performed.
A chest x-ray was taken at the hospital and read by
one expert radiologist at St. John’s Medical College. All
x-rays that were reported as abnormal and as possible
PTB by the first radiologist were read independently by
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two additional radiologists at the same medical college.
Sputum was collected on two consecutive days in a ster-
ile container.
At the laboratory, the consistency of the sputum sample
(i.e. salivary, mucoid, muco-purulent and blood stained)
was noted. The sputum specimens were examined by con-
centrated AFB smear microscopy and processed for cul-
ture. The media used for the culture of Mycobacteria were
Lowenstein-Jensen medium and Mycobacteria growth in-
dicator tube (MGIT) medium. If a specimen was culture-
positive, the species of the isolate was confirmed using the
GenoType Mycobacterium CM kit and the GenoType
MTBC kit (HAIN Lifescience, Germany). Participants
who visited the DGW after the re-consent process had an
additional 3 ml blood drawn to assess immune response
by an in vitro antigen stimulation test (QuantiFERON®-TB
Gold In-Tube test) to identify M. tuberculosis infection.
(Cellestis Limited, Australia, http://www.quantiferon.com/
IRM/content/default.aspx).
The final diagnosis and test results were communi-
cated to the study participant’s parent or guardian and
medical care provider. If the sputum specimen was
smear or culture-positive and/or if the chest x-ray was
abnormal and suggestive of PTB, the results and partici-
pants were also reported to the government tuberculosis
control program (Revised National Tuberculosis Control
Programme – Directly observed short chemotherapy
(RNTCP-DOTS)) for treatment.
Case definitions
If the participant had one sputum culture positive for
Mtb [Isolation of Mtb from either one or both sputum
samples using the GenoType MTBC test kit (HAIN
kit)]; OR one AFB-positive sputum smear AND one
positive PCR for Mtb; OR two AFB-positive sputum
smears, they were considered to have a definite case of
PTB. If the participant was not diagnosed as having def-
inite TB but had a clinical assessment compatible with
pulmonary TB and the chest X-ray was reported to be
“abnormal and suggestive of TB” by at least two of the
three radiologists, they were considered to have a prob-
able case of PTB.
Data management and analysis
All data collected were entered into customized data ac-
quisition software. All data forms were checked for
missing data and clarity of data prior to data entry.
Double data entry was done and disparities reconciled
against the data forms. Descriptive statistics were re-
ported using number and percentages. Total person
years of follow-up were calculated. Incidence of TB with
95 % confidence interval (CI) in the active and passive
surveillance groups was reported. Chi-square test was
used to test the association between types of surveillance,
whether the participant attended the DGW for TB screen-
ing, and re-consent status to other demographic and clin-
ical characteristics of the subjects. P values less than 5 %
were considered statistically significant. All analyses were
done using Statistical Package for Social Sciences Version
22.0 (SPSS, 22.0, SPSS Inc, Chicago, IL, USA).
Results
Of the 12,388 eligible adolescents approached, 3441
males and 3202 females were enrolled; response rates
were 53 and 47 % respectively. There were no differ-
ences in response rates observed between schools or in
the response rates of males and females within a school.
Among the 6643 subjects enrolled, 3102 (male 1728, fe-
male 1374) were followed in active surveillance and
3541 (male 1713, female 1828) were under passive sur-
veillance. Of these adolescents, 59 % (N = 1841) were
still in the study at the end of 2 years in the active sur-
veillance group while 68 % (N = 1185) were still in the
study at the end of 2 years in the passive surveillance
group. A total of 1257 (male 698, female 559) and 1127
(male 527, female 600) subjects withdrew from the active
and passive surveillance groups respectively. Of the 1257
adolescents who withdrew from the active surveillance
group, approximately 2/3 i.e. 68.74 % (N = 864) withdrew
during the re-consenting process, which many partici-
pants found difficult to understand. The remaining
31.26 % (N = 393) withdrew for other various reasons.
The majority of participants left the study area for edu-
cation at other institutions, marriage, or with their fam-
ilies. A minority of subjects “felt sick (not TB symptoms)
and did not want to continue in the study” (N = 3), “had
examinations and withdrew from the study” (N = 2) and
“were fasting during Ramzan (Ramadan) month and
withdrew from the study” (N = 2). All 1127 adolescents
in the passive surveillance group who withdrew from the
study withdrew at the time of re-consent. There were six
deaths reported: four (male 3, female 1) in the active
group and two (male 1, female 1) in the passive group.
Verbal autopsies were done for these participants; no
cause of death was related to tuberculosis.
The baseline characteristics of the study subjects were
published earlier [11, 12]. As per the parent’s interview
at baseline, out of the 6643 participants, 5674 had BCG
immunization at birth and 843 participants had not re-
ceived immunization. The data of the remaining 126
participants was not available. Figure 1 describes the
complete study profile with all TB cases in our adoles-
cent cohort. There were 1314 subjects who were referred
to the DGW for the evaluation of pulmonary TB based
on the criteria outlined earlier. Of these, 589 subjects
attended the diagnostic ward. There were 29 subjects
who attended the DGW as self-referrals. Of these 618
subjects screened for PTB, four subjects were diagnosed
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as having definite TB, four subjects as having probable
TB, and 71 subjects had Non-tuberculous Mycobacteria
(NTM) isolated from their sputum in the active surveil-
lance group. In the passive surveillance group, four sub-
jects were diagnosed as having definite TB, two subjects
with having probable TB, and 48 subjects had NTM iso-
lated from their sputum.
Table 1 describes different characteristics of the 14
definite and probable TB cases. One subject was diag-
nosed as having definite TB at his 3rd visit to the DGW,
while all other subjects were diagnosed at their 1st visit
to DGW. Of the eight culture positive cases, five were
smear positive.
The total person years of follow-up in our study was
12,350; 5419 in the active surveillance group and 6931
in the passive surveillance group. The incidence of defin-
ite TB, probable TB, and definite + probable TB were
64.80 (95 % CI: 30.10–123.00), 48.60 (95 % CI: 19.70–
101.00), and 113.40 (95 % CI: 64.50–185.70) / 100,000
person years respectively in our study. The incidence of
definite + probable TB was 147.60 (95 % CI: 68.50–
180.30) / 100,000 person years in the active surveillance
group and 87 (95 % CI: 35.10–180.00) / 100,000 person
years in the passive surveillance group.
Table 2 describes the subjects who attended the DGW
for PTB evaluation in both the active and passive sur-
veillance groups. The participants who attended the
DGW in the active surveillance group were more likely
to be older males with a recent history of weight loss
and cough for more than 2 weeks compared to those in
the passive surveillance group. The subjects who did not
attend the DGW for PTB evaluation even after referral
by the study team were more likely to be males, not to
have subsequently given their re-consent, and were more
likely to be negative for the TST during the follow-up
compared to those subjects who attended the DGW for
PTB evaluation after referral (Table 3).
Table 4 compares the subjects who re-consented to
continue in the study following the change in study
sponsors compared to those who withdrew from the
study. The adolescents who withdrew were more likely
to be 15–18 years age group and in the passive
Total Subjects 
enrolled – 6643 (3441  
M/ 3202 F)
29 (14M/ 15 F) 
Self Referral
Active 
surveillance -  
16 (10 M/ 6 F)
Passive 
Surveillance – 
13 (4 M/ 9 F)
7 (5 M/ 
2 F) NTM 
isolation
9 (5 M/ 4 F) 
negative for NTM 
and Pulmonary TB
Definite 
TB - 1  
Female 
NTM isolation - 2  
(1 M/ 1 F)





1314 (726 M/ 588 F); Referred by 
study team for diagnostic work 
up
Active Surveillance – 694  
(418 M/ 276 F) Passive Surveillance – 620  
(308 M/ 312 F)
369 (225 M/ 144 F) 
didn’t attend the 
DGW for TB 
evaluation
325(193 M/ 132 F) 
attended the DGW
1 Male subject - 
Radiological 
evidence of TB
Definite TB – 4  
(2 M/ 2 F)
Radiological 
evidence of TB –
3 (2 M/ 1 F)
From 1 female 
NTM was isolated
NTM isolation – 
64 (45 M/ 19 F)
1 male subject’s day 
2 sputum sample 
was positive for AFB 
smear; the same 
sample had shown 
M.scrofulaceum
isolation
246 (141 M/ 105 F) 
negative for NTM and 
pulmonary TB
264(109 M/ 155 F) 
attended the DGW
356(199 M/ 157F) did not 
undergo diagnostic work up 
– but asymptomatic on 
follow up
Sputum was not 
collected – 5 (2 M/ 3 F) 
Definite TB – 3 Female  
subjects
Radiological evidence 
of TB – 2 (1 M/ 1 F) 
NTM isolation – 46  
(26 M/ 20 F)
208 (79 M/ 128 F) 
negative for NTM and 
pulmonary TB
Sputum was not 
collected – 8 (3  
M/ 5 F)
Fig. 1 Study profile and TB cases among the adolescent cohort
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Table 1 Characteristic features of definite and probable TB cases















of follow upCough Fever Haemoptysis Night sweats
1 12–104 Active 3 Male 17 Normal 2/2 2/2 + - - - - + 3/3 Positive 16 706
2 20–116 Active 1 Female 16 Under
weight
2/2 2/2 + + - - - - 3/3 NA 15 472
3 33–266 Active 2 Male 15 Normal 2/2 2/2 + - - - - - 3/3 Positive 24 718
4 42–107 Passive 1 Female 12 Under
weight
2/2 2/2 + - + - - - 3/3 NA 7 721
5 72–601 Active 1 Female 15 Under
weight
2/2 2/2 + + - + - - 3/3 Negative 5 711
6 23–061 Passive 1 Female 17 Normal 0/2 2/2 - - - - - - 0/3 Positive 25 725
7 52–301 Passive 1 Female 15 Under
weight
0/2 1/2 - - - - - - 0/3 Positive 17 725
8 83–013 Passive 1 Female 15 Under
weight
0/2 1/2 - - - - - - 0/3 NA 23 706
9 37–404 Active 1 Female 15 Normal 0/2 0/2 - - - - - - 3/3 Positive 10 706
10 37–430 Active 1 Male 16 Normal 0/2 0/2 - - - - - + 3/3 Positive 19 732
11 40–310 Passive 1 Male 16 Under
weight
0/2 0/2 - - - - - - 3/3 NA 18 706
12 77–503 Active 1 Male 14 Normal 0/2 0/2 - - - - - + 3/3 NA 20 729
13 87–155 Passive 1 Female 14 Normal 0/2 0/2 - - - - - - 3/3 NA 13 722
14 26–101 Active 1 Male 12 Normal - - - - - - 3/3 Positive 22 710
a The details in the table were corresponding to nth visit of the participant
b BAZ body mass index for Age Z – score; WHO cut offs 2007, Growth reference 5–19 years; calculated using WHO – ANTHRO software (version 3.2.2); Underweight (<− 2), Overweight (> +1), Normal (−2 to +1)
c 2/2 = two samples smears were positive for Acid fast bacilli of two samples, 1/2 = one sample positive of two, 0/2 = both samples were negative
d 2/2 = two sputum samples had shown the isolation of Mycobacterium tuberculosis (M.tb) on Geno Type MTBC test kit (HAIN kit) of two samples; 1/2 = one sample had M.tb of two; 0/2 = both samples were negative
for M.tb
e Cumulative response of both parent and subject has been considered in case of history of past TB, TB exposure, Symptoms suggestive of TB
f Recent contact with a TB case at least for 8 h a week; in the period of 3 months
g 3/3 = Radiological evidence of TB - chest x-ray (posterior-anterior view) had been reported as abnormal for TB by three radiologists of three radiologists; 0/3 = No radiologists had reported chest X – ray abnormal
for TB
h QFT quantiferon, NA result Not available














surveillance group. They were also more likely to be
negative for TST during the follow-up period, less likely
to have symptoms suggestive of PTB, and were less
likely to have significant TB exposure during the period
under surveillance.
Discussion
In our study, the incidence density of definite and prob-
able pulmonary TB among adolescents was 113 per
Table 2 Comparison of active/ passive surveillance group
participants to the diagnostic ward in terms of baseline
characteristics and other variables
Variable Active surveillance
(N = 341) (%)
Passive surveillance
(N = 277) (%)
P value
Gender
Male 203 (59.5) 113 (40.8)
Female 138 (40.5) 164 (59.2) <0.001
Age
12–13 years 38 (11.1) 33 (11.9)
14–15 years 171 (50.1) 163 (58.8)
16–17 years 87 (25.5) 72 (26.0) <0.001




22 (6.5) 4 (1.4) 0.002
Significant TB
exposure
17 (5.0) 12 (4.3) 0.84
TST≥ 10 mm 191 (56.0) 186 (67.1) 0.005
TST conversion 69 (20.2) 54 (19.5) 0.84
Symptoms and TST
conversion
1 (0.3) 0 (0.0) N.A
Contact and TST ≥
10 mm
2 (0.6) 0 (0.0) N.A
Symptoms and
TST≥ 10 mm
8 (2.3) 2 (0.7) 0.19
Symptoms and TB
contact
2 (0.6) 0 (0.0) N.A
Self-referral 2 (0.6) 8 (2.9) 0.04
Weight loss≥ 2 weeks
Yes 9 (2.6) 1 (0.4)
No 332 (97.4) 276 (99.6) 0.02
Haemoptysis
Yes 4 (1.2) 2 (0.7)
No 337 (98.8) 275 (99.3) 0.69
Cough≥ 2 weeks
Yes 38 (11.1) 10 (3.6)
No 303 (88.9) 267 (96.4) <0.001
Fever≥ 2 weeks
Yes 18 (5.3) 6 (2.2)
No 323 (94.7) 271 (97.8) 0.05
Night sweats≥
2 weeks
Yes 6 (1.8) 1 (0.4)




Yes 1 (0.3) 1 (0.4)
No 340 (99.7) 276 (99.6) 1.0
Table 2 Comparison of active/ passive surveillance group
participants to the diagnostic ward in terms of baseline
characteristics and other variables (Continued)
Significant TB
exposure
Yes 35 (10.3) 34 (12.3)





68 (19.9) 44 (15.9)
Others 273 (80.1) 233 (84.1) 0.20
Mother’s education
Illiterate 147 (43.1) 127 (45.8)
Primary education
or more
193 (56.6) 149 (53.8) 0.51
Father’s education
Illiterate 82 (24.0) 78 (28.2)
Primary education
or more
258 (75.7) 196 (70.8) 0.23
Type of house walls
Brick 272 (79.8) 235 (84.8)
Others 69 (20.2) 42 (15.2) 0.11
Type of cooking fuel
Wood 283 (83.0) 236 (85.2)
Others 58 (17.0) 41 (14.8) 0.14
Final Diagnosis
Definite TB 4 (1.2) 4 (1.4) 1.0
Radiological
evidence of TB
4 (1.2) 2 (0.7) 0.69
NTM isolated 71 (20.8) 48 (17.3) 0.30
Negative for
Pulmonary TB
254 (74.5) 217 (78.3) 0.29
Missing data: Referral Reason–38 (6.1 %), Mother’s education–2 (0.3 %),
Father’s education–4 (0.6 %), Final Diagnosis–12 (1.9 %)
DGW diagnostic ward, TST tuberculin skin test, N.A not applicable, Referral
reason – Referral criteria to the DGW; Symptoms suggestive of Pulmonary
Tuberculosis (PTB) include Cough ≥ 2 weeks, Fever ≥ 2 weeks, Recent Weight
loss for ≥ 2 weeks, Night sweats ≥ 2 weeks, Haemoptysis; Significant TB
exposure - History of positive TB contact (for more than 8 h/week); Definite TB
– Isolation of Mycobacterium tuberculosis from the either one or both sputum
samples on GenoType MTBC test kit (HAIN kit); Radiological evidence of TB -
chest x-ray (posterior-anterior view) had been reported as abnormal for TB by
at least two radiologists; NTM (Non-Tuberculous Mycobacteria) isolated from
the either one or both sputum samples on GenoType Mycobacterium CM kit
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100,000 person years. The overall incidence of tubercu-
losis reported by WHO in India for all age groups was 170
per 100,000 person year population in 2012, which is
greater than our study results [8]. A lower incidence might
be expected in school-going adolescents than in the gen-
eral population [8]. School-going children may also be
healthier than their counterparts who drop-out of school
due to socio-economic reasons. Data (2012–13) from the
district in which this study was conducted indicate that
the enrolment for students between standards I-V was
92 %, VI to VII 84 %, and VIII to X 75 %. The majority of
our enrolments in the study were between standards VII
and X [13]. School enrolment and drop-out rates vary
across ages and gender [14]; being female and reasons re-
lated to poverty and economic reasons were major factors
associated with drop-outs [15]. Thus, our study sample is
likely to have had a smaller proportion of the very poor
compared to the general population, which may be also
the reason for lower incidence in our study.
In our study, the incidence of culture-positive PTB was
65 per 100,000 person years. Data in an earlier study con-
ducted by the Tuberculosis Research Center, Chennai,
Chingleput district, South India was 90 per 100,000 per-
son year population among 10–24 year olds during the
period of 1984–1986 [16]. The reduction in incidence may
be attributed to a secular change in the incidence with the
implementation of Revised National Tuberculosis Control
Programme and the smaller age range of our study sub-
jects. Similar studies in adolescents conducted in Eastern
Uganda and South Africa show an overall incidence of
235 per 100,000 person years and 450 per 100,000 person
years respectively [17, 18]. However, these countries have
a higher prevalence of TB in general, compared to India,
and higher rates of human immunodeficiency virus (HIV).
HIV status was not evaluated in our study population;
however, data from the area indicate that the HIV preva-
lence among antenatal clinic attendees in Chittoor district
between 2010 and 2011 was 0.50 to 1.00 % and the
Table 3 Comparison of responders/ non responders to the
diagnostic ward in terms of baseline characteristics and other
variables
Variable Attended DGW for
TB screeninga
(Responders)
(N = 589) (%)
Didn’t attend
the DGW (Non –
Responders)
(N = 725) (%)
P value
Gender
Male 302 (51.3) 424 (58.5) 0.01
Female 287 (48.7) 301 (41.5)
Age
12 years 175 (29.7) 170 (23.4) 0.08
13–14 years 296 (50.3) 391 (53.9)
15–16 years 95 (16.1) 129 (17.8)
17–18 years 23 (3.9) 35 (4.8)
Surveillance
Active 325 (55.2) 369 (50.9) 0.12





104 (17.7) 139 (19.2) 0.48
Others 485 (82.3) 586 (80.82)
Mother’s education
Illiterate 259 (44.0) 347 (47.9) 0.18
Primary education
or more
328 (55.7) 378 (52.1)
Father’s education
Illiterate 151 (25.6) 214 (29.5) 0.12
Primary education
or more
434 (73.7) 506 (69.8)
Type of house walls
Brick 482 (81.83) 575 (79.3) 0.25
Others 107 (18.2) 150 (20.7)
Type of cooking fuel
Wood 492 (83.5) 629 (86.8) 0.1
Others 97 (16.5) 96 (13.2)
TST Positivity during 2
years of follow - up
Yes 545 (92.5) 646 (89.1) 0.03
No 44 (7.5) 79 (10.9)
Symptoms suggestive
of TB during the
2 years follow – up
Yes 51 (8.7) 54 (7.4) 0.42
No 538 (91.3) 671 (92.6)
Significant TB exposure
during the 2 years
follow – up
Yes 42 (7.1) 35 (4.8) 0.8
Table 3 Comparison of responders/ non responders to the
diagnostic ward in terms of baseline characteristics and other
variables (Continued)
No 547 (92.9) 690 (95.2)
Re - consent Status
Yes (Given) 546 (92.7) 510 (70.3) <0.01
No (Not given) 43 (7.3) 211 (29.1)
Missing data: Mother’s education – 2 (0.2 %), Father’s education – 9 (0.7 %), Re
– consent status – 4 (0.4 %)
a Does not include 29 participants who have attended the DGW without
referral during the follow–up
DGW diagnostic ward, TST tuberculin skin test, Symptoms suggestive of
Pulmonary Tuberculosis (PTB) include Cough ≥ 2 weeks, Fever ≥ 2 weeks,
Recent Weight loss for ≥ 2 weeks, Night sweats ≥ 2 weeks, Haemoptysis;
Significant TB exposure - History of positive TB contact (for more
than 8 h/week)
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prevalence of HIV in Andhra Pradesh state among adults
was 0.90 % [19].
Reliable epidemiological data on TB among adolescents
is essential for accurate study design and planning for vac-
cine efficacy trials [20–22]. In India, the only available data
among the adolescent age group, until now, is RNTCP
data. Our study data aims to supplement the RNTCP data
and to provide the additional details needed to conduct
TB vaccine trials among adolescents in India.
The strengths of our study are the relatively large sam-
ple size, the detailed work up at baseline, the in-depth
diagnostic evaluation, and the follow-up of participants
in all clinics and hospitals within and surrounding the
study area. The data available about response rates of
schools at the time of enrolment into the study suggest
that there is unlikely to be a responder bias; however,
detailed health history was unavailable for the non-
responders to exclude this bias completely. The major
limitation was the loss to follow-up that followed the
change in the study sponsor that led to re-consenting
subjects. Approximately 59 % were still in the study at
2 years in the active surveillance group and 68 %
remained in the passive surveillance group. However, we
do not believe that this loss to follow-up would have led
to a decrease in the numbers of TB patients we detected,
since weekly surveillance of clinics and hospitals within
the study area and in the surrounding areas after the re-
consent period did not reveal any new PTB cases from
within our project area in the study age group. Another
limitation was that only 44.80 % of the patients referred
to the diagnostic ward for screening actually underwent
the procedures. However, we do not believe that this
would have resulted in a significant underestimate of the
Table 4 Comparison of those who re – consented to those
who did not re – consent following a change in study
sponsorship
Variable Re – consent
givena
(N = 4647) (%)
Re – consent
was not givenb,c
(N = 1937) (%)
P value
Gender
Male 2427 (52.2) 978 (50.5) 0.2
Female 2220 (47.8) 959 (49.5)
Age
12 years 1383 (29.8) 392 (20.3) <0.01
13–14 years 2453 (52.8) 1035 (53.4)
15–16 years 675 (14.5) 415 (21.4)
17–18 years 136 (2.9) 95 (4.9)
Surveillance
Active 2235 (48.1) 808 (41.7) <0.01





878 (18.9) 340 (17.6) 0.2
Others 3769 (81.1) 1597 (82.4)
Mother’s education
Illiterate 2221 (47.8) 954 (49.3) 0.3
Primary education
or more
2420 (52.1) 982 (50.7)
Father’s education
Illiterate 1210 (26.0) 501 (25.9) 0.86
Primary education
or more
3416 (73.5) 1430 (73.8)
Type of house walls
Brick 3674 (79.1) 1545 (79.8) 0.52
Others 973 (20.9) 392 (20.2)
Type of cooking fuel
Wood 3990 (85.9) 1653 (85.3) 0.58
Others 657 (14.1) 284 (14.7)
TST Positivity during
the follow - up
Yes 949 (20.4) 240 (12.4) <0.01
No 3698 (79.6) 1697 (87.6)
Symptoms suggestive
of TB during the
follow – up
Yes 96 (2.1) 7 (0.4) <0.01
No 4551(97.9) 1930 (99.6)
Significant TB exposure
during the 2 years follow – up
Yes 65 (1.4) 12 (0.6) 0.01
No 4582 (98.6) 1925 (99.4)
Table 4 Comparison of those who re – consented to those
who did not re – consent following a change in study
sponsorship (Continued)
Referral to DGW Status
Attended the DGW 546 (11.7) 43 (2.2) <0.01
Didn’t attend the DGW
even after referral
510 (11.0) 211 (10.9)
Visited DGW even
without referral
during follow - up
25 (0.5) 4 (0.2)
Missing data: Mother’s education – 7 (0.1 %), Father’s education – 27 (0.3 %)
a Among the 4647 adolescents one death was reported after re-consent
process in active surveillance group which is also included in the table
b Fifty-nine subjects in active surveillance group whose day 720 form filled
(closure of the study) before the re – consenting process data was considered
as missing data. Of these three deaths were reported
c There were two deaths reported after re-consent process in the passive sur-
veillance group whose number is included in the table
DGW diagnostic ward, TST – tuberculin skin test, Symptoms suggestive of
Pulmonary Tuberculosis (PTB) include Cough ≥ 2 weeks, Fever ≥ 2 weeks,
Recent Weight loss for ≥ 2 weeks, Night sweats ≥ 2 weeks, Haemoptysis;
Significant TB exposure - History of positive TB contact (for more
than 8 h/week)
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incidence given that during follow-up in the field, the
55.20 % of participants who did not undergo the diag-
nostic procedures did not worsen in health and did not
attend any clinics or health centres under surveillance
during the study. Indeed, the surveillance of the health
centres was undertaken to particularly address the likeli-
hood that participants might not be seen by the study
physicians but might access other health providers in
and around the study area. Fifty four participants who
were suspected for TB and had symptoms suggestive of
TB at the 2 year follow-up did not attend the diagnostic
ward for TB diagnosis confirmation. These participants
and others who did not attend the diagnostic ward were
considered to not have TB in the analysis.
Conclusion
The incidence of pulmonary tuberculosis among adoles-
cents in our study is much lower than similar studies
conducted in South Africa and Eastern Uganda, which
may be partly attributed to low incidence of HIV in
India. The study data with higher incidence of PTB in
active surveillance compared to passive surveillance
method will help inform the design of future TB vaccine
efficacy trials among adolescents in India.
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